Table 3 Univariable and multivariable analysis: PFS.
Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
Variable | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
Age (decades) | 1.08 (0.90–1.29) | 0.43 | 1.11 (0.91–1.37) | 0.31 |
Prior BCMA exposure | ||||
No | 1 | 1 | ||
Yes | 1.80 (1.21–2.68) | 0.004 | 1.82 (1.19–2.79) | 0.006 |
EMD | ||||
No | 1 | 1 | ||
Yes | 2.09 (1.22–3.61) | 0.008 | 1.28 (0.71–2.31) | 0.42 |
Unknown | 1.67 (1.05–2.65) | 0.03 | 1.10 (0.61–1.99) | 0.76 |
ECOG PS | ||||
ECOG 0 | 1 | 1 | ||
ECOG 1 | 1.00 (0.42–2.26) | 1 | 0.67 (0.28–1.60) | 0.36 |
ECOG 2 | 1.43 (0.54–3.79) | 0.47 | 0.89 (0.33–2.44) | 0.83 |
ECOG 3 | 4.39 (1.63–11.82) | 0.003 | 3.70 (1.23–11.13) | 0.02 |
Unknown | 2.01 (0.91–4.46) | 0.09 | 1.23 (0.50–3.15) | 0.67 |
Cytogenetic Risk | ||||
Standard-risk | 1 | 1 | ||
High-risk | 1.65 (1.05–2.60) | 0.03 | 1.38 (0.86–2.21) | 0.18 |
Unknown | 1.30 (0.75–2.24) | 0.35 | 1.50 (0.84–2.66) | 0.17 |
Platelet count at start of teclistamab | ||||
≥50 × 109/L | 1 | 1 | ||
<50 × 109/L | 2.99 (1.90-4.83) | <0.001 | 3.18 (1.90–5.35) | <0.001 |
Penta-drug refractory | ||||
No | 1 | 1 | ||
Yes | 1.66 (1.05–2.63) | 0.03 | 1.34 (0.79–2.27) | 0.28 |
Unknown | 1.59 (0.95–2.66) | 0.08 | 1.48 (0.76–2.88) | 0.25 |
